Michael Andrew Vavuranakis

Michael Andrew Vavuranakis

Auto-generated profile, based on publicly available information

Michael Andrew Vavuranakis

3rd Department of Cardiology, Medical School, National and Kapodistrian University of Athens, Sotiria Chest Disease Hospital, 11527 Athens, Greece

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
VTVasiliki Tsigkou
Vasiliki Tsigkou
EVANGELOS OIKONOMOUEVANGELOS OIKONOMOU
EVANGELOS OIKONOMOU
AAArtemis Anastasiou
Artemis Anastasiou
Stamatios LampsasStamatios Lampsas
Stamatios Lampsas
George E. ZakynthinosGeorge E. Zakynthinos
George E. Zakynthinos
GSGerasimos Siasos
Gerasimos Siasos
Heart failure is a complex medical syndrome that is attributed to a number of risk factors; nevertheless, its clinical presentation is quite similar among the different etiologies. Heart failure displays a rapidly increasing prevalence due to the aging of the population and the success of medical treatment and devices. The pathophysiology of heart failure comprises several mechanisms, such as activation of neurohormonal systems, oxidative stress, dysfunctional calcium handling, impaired energy utilization, mitochondrial dysfunction, and inflammation, which are also implicated in the development of endothelial dysfunction. Heart failure with reduced ejection fraction is usually the result of myocardial loss, which progressively ends in myocardial remodeling. On the other hand, heart failure with preserved ejection fraction is common in patients with comorbidities such as diabetes mellitus, obesity, and hypertension, which trigger the creation of a micro-environment of chronic, ongoing inflammation. Interestingly, endothelial dysfunction of both peripheral vessels and coronary epicardial vessels and microcirculation is a common characteristic of both categories of heart failure and has been associated with worse cardiovascular outcomes. Indeed, exercise training and several heart failure drug categories display favorable effects against endothelial dysfunction apart from their established direct myocardial benefit.

21 March 2022 in The American Journal of Cardiology
Verified
Journal Article
Closed access
MVMichael A. Vavuranakis
Michael A. Vavuranakis
SJSteven R. Jones
Steven R. Jones
EZEfthymios Ziogos
Efthymios Ziogos
MBMichael J. Blaha
Michael J. Blaha
MWMarlene S. Williams
Marlene S. Williams
TLThorsten M. Leucker
Thorsten M. Leucker

8 October 2020 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
MVMichael A. Vavuranakis
Michael A. Vavuranakis
SJSteven R. Jones
Steven R. Jones
RCRhanderson Cardoso
Rhanderson Cardoso
GGGary Gerstenblith
Gary Gerstenblith
TLThorsten M. Leucker
Thorsten M. Leucker
High lipoprotein(a) [Lp(a)] levels are associated with the development of atherosclerotic cardiovascular disease (ASCVD) and with calcific aortic valve stenosis (CAVS) both observationally and causally from human genetic studies. The mechanisms are not well characterized but likely involve its role as a carrier of oxidized phospholipids (OxPLs), which are known to be increased in pro-inflammatory states, to induce pro-inflammatory changes in monocytes leading to plaque instability, and to impair vascular endothelial cell function, a driver of acute and recurrent ischemic events. In addition, Lp(a) itself has prothrombotic activity. Current lipid-lowering strategies do not sufficiently lower Lp(a) serum levels. Lp(a)-specific-lowering drugs, targeting apolipoprotein(a) synthesis, lower Lp(a) by up to 90% and are being evaluated in ongoing clinical outcome trials. This review summarizes the current knowledge on the associations of Lp(a) with ASCVD and CAVS, the current role of Lp(a) assessment in the clinical setting, and emerging Lp(a)-specific-lowering therapies.

7 November 2022 in Life
Verified
Journal Article
Open access
PDF file
EVANGELOS OIKONOMOUEVANGELOS OIKONOMOU
EVANGELOS OIKONOMOU
PTPanagiotis Theofilis
Panagiotis Theofilis
Stamatios LampsasStamatios Lampsas
Stamatios Lampsas
OKOurania Katsarou
Ourania Katsarou
KKKonstantinos Kalogeras
Konstantinos Kalogeras
GSGerasimos Siasos
Gerasimos Siasos
Over the last decades, significant advances have been achieved in the treatment of coronary artery disease (CAD). Proper non-invasive diagnosis and appropriate management based on functional information and the extension of ischemia or viability remain the cornerstone in the fight against adverse CAD events. Stress echocardiography and single photon emission computed tomography are often used for the evaluation of ischemia. Advancements in non-invasive imaging modalities such as computed tomography (CT) coronary angiography and cardiac magnetic resonance imaging (MRI) have not only allowed non-invasive imaging of coronary artery lumen but also provide additional functional information. Other characteristics regarding the plaque morphology can be further evaluated with the latest modalities achieving a morpho-functional evaluation of CAD. Advances in the utilization of positron emission tomography (PET), as well as software advancements especially regarding cardiac CT, may provide additional prognostic information to a more evidence-based treatment decision. Since the armamentarium on non-invasive imaging modalities has evolved, the knowledge of the capabilities and limitations of each imaging modality should be evaluated in a case-by-case basis to achieve the best diagnosis and treatment decision. In this review article, we present the most recent advances in the noninvasive anatomical and functional evaluation of CAD.

6 June 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
KKKonstantinos Kalogeras
Konstantinos Kalogeras
RJRichard J. Jabbour
Richard J. Jabbour
RPRadoslaw Pracon
Radoslaw Pracon
TKTito Kabir
Tito Kabir
JSJoanne Shannon
Joanne Shannon
VPVasileios Panoulas
Vasileios Panoulas
Background: No data currently exist comparing the contemporary iterations of balloon‐expandable (BE) Edwards SAPIEN 3/Ultra and the self‐expanding (SE) Medtronic Evolut PRO/R34 valves. The aim of the study was the comparison of these transcatheter heart valves with emphasis on patients with small aortic annulus. Methods and Results: In this retrospective registry, periprocedural outcomes and midterm all‐cause mortality were analyzed. A total of 1673 patients (917 SE versus 756 BE) were followed up for a median of 15 months. A total of 194 patients died (11.6%) during follow‐up. SE and BE groups showed similar survival at 1 (92.6% versus 90.6%) and 3 (80.3% versus 85.2%) years ( P log‐rank =0.136). Compared with the BE group, patients treated with the SE device had lower peak (16.3±8 mm Hg SE versus 21.9±8 mm Hg BE) and mean (8.8±5 mm Hg SE versus 11.5±5 mm Hg BE) gradients at discharge. Conversely, the BE group demonstrated lower rates of at least moderate paravalvular regurgitation postoperatively (5.6% versus 0.7% for SE and BE valves, respectively; P <0.001). In patients treated with small transcatheter heart valves (≤26 mm for SE and ≤23 mm for BE; N=284 for SE and N=260 for BE), survival was higher among patients treated with SE valves at both 1 (96.7% SE versus 92.1% BE) and 3 (91.8% SE versus 82.2% BE) years ( P log‐rank =0.042). In propensity‐matched patients treated with small transcatheter heart valve, there remained a trend for higher survival among the SE group at both 1 (97% SE versus 92.3% BE) and 3 years (91.8% SE versus 78.7% BE), P log‐rank =0.096). Conclusions: Real‐world comparison of the latest‐generation SE and BE devices demonstrated similar survival up to 3 years’ follow‐up. In patients with small transcatheter heart valves, there may be a trend for improved survival among those treated with SE valves.

1 September 2021 in The American Journal of Cardiology
Verified
Journal Article
Closed access
MVMichael A. Vavuranakis
Michael A. Vavuranakis
CKCharalampos Kalantzis
Charalampos Kalantzis
VVVassilis Voudris
Vassilis Voudris
EKElias Kosmas
Elias Kosmas
KKKonstantinos Kalogeras
Konstantinos Kalogeras
MVManolis Vavuranakis
Manolis Vavuranakis